Alvotech (ALVO)

Dec 23, 2024, 4:00 AM EST - 25 days ago

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

Nov 21, 2024, 2:02 AM EST - 2 months ago

Alvotech's Position In The Coming Biosimilar Gold Rush

Nov 15, 2024, 8:00 AM EST - 2 months ago

Certain Closed-end Funds Advised by Franklin Templeton Fund Adviser, LLC Announce Appointment of New Chair and Directors

Nov 14, 2024, 1:59 PM EST - 2 months ago

Alvotech (ALVO) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 8:00 AM EST - 2 months ago

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024

Nov 4, 2024, 7:00 AM EST - 2 months ago

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)

Oct 25, 2024, 8:00 AM EDT - 3 months ago

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Oct 10, 2024, 5:01 AM EDT - 3 months ago

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Oct 2, 2024, 12:08 PM EDT - 3 months ago

Alvotech (ALVO) Shares Up 3.77% on Oct 2

Sep 25, 2024, 5:01 AM EDT - 4 months ago

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

Aug 26, 2024, 9:15 AM EDT - 5 months ago

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 26, 2024, 8:00 AM EDT - 5 months ago

Alvotech: Steady Progress Offers A Good Chance Of Upside

Aug 16, 2024, 10:27 AM EDT - 5 months ago

Alvotech (ALVO) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 4:15 PM EDT - 5 months ago

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

Aug 15, 2024, 4:30 AM EDT - 5 months ago

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Aug 1, 2024, 4:02 PM EDT - 6 months ago

Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET

Jul 22, 2024, 6:35 AM EDT - 6 months ago

STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe

Jul 11, 2024, 4:45 AM EDT - 6 months ago

Alvotech Announces Closing of Private Debt Financing

Jul 1, 2024, 5:35 PM EDT - 7 months ago

Alvotech Issues New Shares to Holders of Convertible Bonds

Jul 1, 2024, 5:10 AM EDT - 7 months ago

Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024

Jun 26, 2024, 4:50 AM EDT - 7 months ago

Alvotech Receives Conversion Notices for Majority of Convertible Bonds

Jun 18, 2024, 4:01 AM EDT - 7 months ago

Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe

Jun 11, 2024, 4:00 AM EDT - 7 months ago

Alvotech and STADA add to Strategic Alliance through Denosumab Partnership

Jun 11, 2024, 4:00 AM EDT - 7 months ago

Alvotech and STADA add to strategic alliance through denosumab partnership

Jun 7, 2024, 4:00 AM EDT - 8 months ago

Alvotech Announces Strategic Refinancing Agreement

May 29, 2024, 8:05 AM EDT - 8 months ago

Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024

May 22, 2024, 12:55 PM EDT - 8 months ago

Alvotech (ALVO) Q1 2024 Earnings Call Transcript

May 21, 2024, 5:15 PM EDT - 8 months ago

Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

May 21, 2024, 8:01 AM EDT - 8 months ago

Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK

May 20, 2024, 8:25 PM EDT - 8 months ago

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

May 20, 2024, 8:25 PM EDT - 8 months ago

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

May 15, 2024, 9:30 AM EDT - 8 months ago

Alvotech S.A. Annual General Meeting to be held June 7, 2024

May 13, 2024, 8:00 AM EDT - 8 months ago

Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)

May 2, 2024, 7:15 AM EDT - 9 months ago

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024

Apr 30, 2024, 4:00 AM EDT - 9 months ago

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

Apr 24, 2024, 4:00 AM EDT - 9 months ago

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)

Apr 19, 2024, 6:10 AM EDT - 9 months ago

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

Apr 16, 2024, 5:43 PM EDT - 9 months ago

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

Apr 3, 2024, 7:41 AM EDT - 10 months ago

Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

Mar 22, 2024, 4:15 PM EDT - 10 months ago

Alvotech Announces Increase in Number of Own Shares

Mar 21, 2024, 2:58 PM EDT - 10 months ago

Alvotech (ALVO) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 4:15 PM EDT - 10 months ago

Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

Mar 5, 2024, 4:01 PM EST - 11 months ago

Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET

Feb 29, 2024, 4:05 PM EST - 11 months ago

Alvotech Appoints Interim Chief Quality Officer

Feb 26, 2024, 4:25 AM EST - 11 months ago

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

Feb 23, 2024, 8:15 PM EST - 11 months ago

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

Feb 15, 2024, 7:00 AM EST - 1 year ago

Alvotech settles with J&J to launch Stelara biosimilar in Europe, Canada

JNJ

Feb 15, 2024, 6:30 AM EST - 1 year ago

Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)

Jan 29, 2024, 4:00 AM EST - 1 year ago

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Jan 19, 2024, 11:30 AM EST - 1 year ago

Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04